This study was previously presented at The Anxiety Disorders Association of America (ADAA) 29th Annual Conference, New Mexico, 12–15 March 2009, The 8th International Forum on Mood and Anxiety Disorders (IFMAD), Vienna, 12–14 November 2008, and The American College of Neuropsychopharmacology (ACNP) 47th Annual Conference, Arizona, 7–11 December 2008.
Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder†
Version of Record online: 16 OCT 2012
Copyright © 2012 John Wiley & Sons, Ltd.
International Journal of Geriatric Psychiatry
Volume 28, Issue 6, pages 615–625, June 2013
How to Cite
Mezhebovsky, I., Mägi, K., She, F., Datto, C. and Eriksson, H. (2013), Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder. Int. J. Geriat. Psychiatry, 28: 615–625. doi: 10.1002/gps.3867
- Issue online: 6 MAY 2013
- Version of Record online: 16 OCT 2012
- Manuscript Accepted: 12 JUL 2012
- Manuscript Received: 15 FEB 2012
- AstraZeneca Pharmaceuticals. Grant Number: NCT00389064
Supporting information may be found in the online version of this article.
|gps_3867_sm_figuresandtables.docx||Word 2007 document||108K||Supplementary Material|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.